Molecular Partners AG (XSWX:MOLN)
CHF 3.305 -0.115 (-3.36%) Market Cap: 108.63 Mil Enterprise Value: -74.61 Mil PE Ratio: 0 PB Ratio: 0.62 GF Score: 53/100

Molecular Partners AG at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 06:05PM GMT
Release Date Price: CHF5.97 (-0.67%)
Alistair Campbell
RBC Capital Markets - Analyst

We'll continue this afternoon sessions. I'm Alistair Campbell, senior analyst for our European healthcare team. It's my pleasure now to have a session with Molecular Partners, being represented by CEO, Patrick Amstutz, and Seth Lewis.

Questions & Answers

Alistair Campbell
RBC Capital Markets - Analyst

What I'd like to do is just maybe start, Patrick, with just an overview, given the industry has numerous binder technologies that we're all quite familiar with for pharmaceutical applications, whether that be antibodies, antibody fragments, aptamers, [aphamers]. Your program is DARPins, so maybe we can start with an overview of the DARPin technology, its key differentiating factors, and what proof of concept data you've achieved with the platform thus far.

Patrick Amstutz
Molecular Partners AG - CEO and Management Board Member, Board Member

First of all, thanks for the invitation. We're enjoying the conference here, enjoying New York, and having many good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot